2010
DOI: 10.1016/j.jclinane.2009.06.002
|View full text |Cite
|
Sign up to set email alerts
|

Bradycardia leading to asystole during dexmedetomidine infusion in an 18 year-old double-lung transplant recipient

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

3
29
0
1

Year Published

2010
2010
2019
2019

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 40 publications
(36 citation statements)
references
References 26 publications
3
29
0
1
Order By: Relevance
“…DEX has been increasingly used for operative anesthesia and in the pediatric intensive care unit for postoperative care (4 -6). Its ability to induce sedation and analgesia enable it to serve as a sole sedative or as an adjunct drug during mechanical ventilation and/or sedation-dependent procedures (7)(8)(9). The terminal half-life of DEX established in adult patients is 110 mins (10) and the drug was approved by the Food and Drug Administration for continuous infusion of 0.2 to 0.7 g/kg/hr for up to 24 hrs for sedation (7,11).…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…DEX has been increasingly used for operative anesthesia and in the pediatric intensive care unit for postoperative care (4 -6). Its ability to induce sedation and analgesia enable it to serve as a sole sedative or as an adjunct drug during mechanical ventilation and/or sedation-dependent procedures (7)(8)(9). The terminal half-life of DEX established in adult patients is 110 mins (10) and the drug was approved by the Food and Drug Administration for continuous infusion of 0.2 to 0.7 g/kg/hr for up to 24 hrs for sedation (7,11).…”
mentioning
confidence: 99%
“…Its ability to induce sedation and analgesia enable it to serve as a sole sedative or as an adjunct drug during mechanical ventilation and/or sedation-dependent procedures (7)(8)(9). The terminal half-life of DEX established in adult patients is 110 mins (10) and the drug was approved by the Food and Drug Administration for continuous infusion of 0.2 to 0.7 g/kg/hr for up to 24 hrs for sedation (7,11). A preliminary study in pediatric patients has established the terminal half-life of DEX to be 2.65 (Ϯ 0.88 hrs) (12); the safety and effectiveness in children Ͻ18 yrs of age are now being studied but have not yet been established (13).…”
mentioning
confidence: 99%
“…25 In rare cases, sinus arrest has been reported. 26,27 Hypotension and bradycardia appear to occur at lower rates in children. In 1 large trial of more than 1200 children, the reported incidence of hypotension was 2.2%, and in another trial of dexmedetomidine in 315 children with behavioral disorders, the incidence of hypotension and/or bradycardia was ,3%.…”
Section: Discussionmentioning
confidence: 99%
“…Medicamentos como la dexmedetomidina han demostrado una adecuada respuesta clínica y baja tasa de complicaciones respiratorias, así como menor incidencia de delirium (10)(11)(12)(13)(14) A pesar de los beneficios de dexmedetomidina para sedación, también se ha asociado a eventos adversos graves como bradicardia severa, hipotensión e incluso, paro cardiaco (15)(16)(17). Su uso en diferentes procedimientos, asociados a diferentes modalidades de anestesia tambien se ha visto relacionado con episodios de bradicardia, que requieren de manejo con atropina para la prevención de complicaciones hemodinámicas mas severas (18,19). Sin embargo, no se conocen estudios respecto a las complicaciones cardiovasculares en procedimientos como la cirugía microgá-fica de Mohs con requerimiento de sedación.…”
Section: Introductionunclassified